New immune cell combo targets hard-to-treat lymphoma
NCT ID NCT05618925
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 32 times
Summary
This early-phase study tests a new treatment called CD19 t-haNK, a type of immune cell designed to attack lymphoma cells. It is given alone or with two other drugs (N-803 and rituximab) to up to 20 adults whose Non-Hodgkin lymphoma has returned or not responded to at least two prior therapies. The main goal is to check safety, and researchers will also measure how well the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN'S LYMPHOMA REFRACTORY/RELAPSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Texas Oncology
RECRUITINGTyler, Texas, 75702, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.